Daily FNArena News

REVA Medical has commenced recruiting for a CE Mark trial of its new stent product, which has Bell Potter assessing the potential of the stock.

The Chartist expects further volatility in the Aussie dollar, with the US$0.94 level looming as a test of critical technical support.

The low AUD is already impacting on the Australian Healthcare sector in terms of positive earnings forecast and target revisions.

Weekly update on recommendation, target price, and earnings forecast changes.

This week’s Tweets on Twitter by Your Editor.

It has become a popular theme among investors: do beaten down services providers now provide value opportunities or not? The FNArena editor responds to questions.

According to the May Investor Sentiment Survey, investors remain cautiously optimistic, awaiting opportunities to allocate more funds into Australian shares.

A wrap of the day’s activity on the Australian stock market.

The way ahead looks familiar for Wesfarmers. The high road is Coles, Bunnings and Kmart. Centre line is Officeworks, Insurance. The low road is Target, Coal and Chemical/Industrial divisions.

Austbrokers has acquired two more insurance agencies, adding to a division that’s expected to write over $210m on an annualised basis.